https://medicalxpress.com/ en-us Medical Xpress internet news portal provides the latest news on Health and Medicine. A KAIST research team has identified the real reason why anticancer drugs kill cancer cells—targeted anticancer therapies do not simply block cancer proteins but rather shut down the "protein factories" inside the cells, forcing them to undergo self-destruction. Consequently, the "two-faced protein" that plays a key role in this process is gaining attention as a breakthrough for treating patients with drug resistance. https://medicalxpress.com/news/2026-04-protein-discovery-leukemia-drugs-succeed.html Thu, 23 Apr 2026 12:20:03 EDT news696164761 A new study has identified taurine, which is made naturally in the body and consumed through some foods, as a key regulator of myeloid cancers such as leukemia. The paper is published in Nature. https://medicalxpress.com/news/2025-05-downside-taurine-leukemia-growth-aiding.html Wed, 14 May 2025 11:00:10 EDT news666430262 Scientists from Duke-NUS Medical School and their collaborators have identified an inherited genetic variation prevalent among East Asians that contributes to drug resistance, driving the aggressive growth of cancer cells in patients with chronic myeloid leukemia. https://medicalxpress.com/news/2024-11-inhibiting-specific-protein-action-precision.html Thu, 07 Nov 2024 15:40:34 EST news650216430 A key gene that could enhance the treatment success rates of chronic myeloid leukemia (CML) has been discovered by researchers. https://medicalxpress.com/news/2024-10-discovery-key-gene-chronic-myeloid.html Mon, 07 Oct 2024 09:34:03 EDT news647512441 Researchers leading the SWOG S1712 clinical trial have found that adding ruxolitinib to standard tyrosine kinase inhibitor (TKI) treatment for patients with chronic-phase chronic myeloid leukemia (CP-CML) significantly increased the percentage of patients who had a molecular response deep enough to warrant discontinuing treatment. https://medicalxpress.com/news/2024-09-clinical-trial-adding-ruxolitinib-tyrosine.html Mon, 23 Sep 2024 16:41:03 EDT news646328461 According to researchers at The University of Texas MD Anderson Cancer Center, 80% of patients with previously untreated or relapsed/refractory advanced-phase chronic myeloid leukemia (CML)—including both accelerated or myeloid blast phases of the disease—or Philadelphia chromosome-positive acute myeloid leukemia (AML) achieved a bone marrow remission when treated with a novel combination of decitabine, venetoclax and ponatinib. https://medicalxpress.com/news/2024-09-treatment-regimen-yields-response-advanced.html Wed, 18 Sep 2024 11:36:33 EDT news645878189 A novel assay that detects a unique molecular marker in patients with acute myeloid leukemia (AML) may revolutionize the way this disease is detected and treated according to a new report in The Journal of Molecular Diagnostics. This assay may improve the detection of AML driven by KMT2A gene fusions and may affect treatment decision-making, assessing response to therapy, and long-term surveillance. https://medicalxpress.com/news/2023-11-assay-revolutionize-treatment-acute-myeloid.html Mon, 13 Nov 2023 11:41:09 EST news619098065 Scientists at Duke-NUS Medical School, A*STAR's Genome Institute of Singapore (GIS), Singapore General Hospital (SGH) and their colleagues in Singapore have used artificial intelligence (AI) to accelerate the discovery of critical biomarkers that can predict, at diagnosis, patients with chronic myeloid leukemia (CML) who will not respond to conventional treatment. With this early prognosis, such patients could receive a life-saving bone marrow transplant during the early stages of the disease. https://medicalxpress.com/news/2023-06-leukemia-treatment-response-crystal-ball-ai.html Thu, 01 Jun 2023 12:27:04 EDT news604841221 Chronic myeloid leukemia (CML) is a type of blood cancer that arises from malignant changes in blood-forming cells of the bone marrow. It mainly occurs in older individuals and represents about 20% of all adult leukemia cases. https://medicalxpress.com/news/2023-05-mast-cells-shown-important-impact.html Tue, 16 May 2023 14:38:15 EDT news603466692 Researchers at University of California San Diego School of Medicine, Sanford Stem Cell Institute and Moores Cancer Center report that a late-stage, pre-clinical small molecule inhibitor, called rebecsinib, reverses malignant hyper-editing by an inflammation-induced protein isoform, known as ADAR1 p150. This malignant protein isoform of ADAR1 promotes immune silencing, metastasis and therapeutic resistance in 20 different cancer types. https://medicalxpress.com/news/2023-02-small-molecule-drug-reverses-adar1-induced.html Thu, 16 Feb 2023 13:03:40 EST news595775016 A combination of ponatinib and blinatumomab was found to be safe and highly effective in patients with newly diagnosed or relapsed/refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (ALL), according to researchers at The University of Texas MD Anderson Cancer Center. The study may support a regimen to produce complete remission with front-line therapy, without the increased risks associated with systemic chemotherapy or a stem cell transplant. https://medicalxpress.com/news/2021-05-combination-therapy-high-response-patients.html Thu, 20 May 2021 03:47:13 EDT news540701228 Scientists have shown that two existing drug candidates—JAK inhibitors and Mepron—hold potential as treatments for a deadly acute myeloid leukemia (AML) subtype that is more common in children. https://medicalxpress.com/news/2021-04-scientists-potential-drug-candidates-deadly.html Wed, 14 Apr 2021 07:45:51 EDT news537605145 A research team at Inselspital, Bern University Hospital and the University of Bern has identified and tested the use of an agent that can effectively inhibit the proliferation of leukemia stem cells. Metoclopramide (MPR), used as an anti-emetic medication, interrupts the unique CD93 signaling pathway that only leukemia stem cells use to proliferate. This opens up a therapeutic approach using MPR to selectively eliminate leukemia stem cells. https://medicalxpress.com/news/2021-01-metoclopramide-inhibits-proliferation-leukemia-stem.html Wed, 27 Jan 2021 07:48:56 EST news530956131 A team of researchers at University of California San Diego School of Medicine and Moores Cancer Center used CRISPR technology to identify key regulators of aggressive chronic myeloid leukemia, a type of cancer that remains difficult to treat and is marked by frequent relapse. https://medicalxpress.com/news/2020-04-leukemia-weakness-genome-wide-crispr-technology.html Mon, 20 Apr 2020 13:01:47 EDT news506606503 Scientists and clinicians from Duke-NUS Medical School, the Agency for Science, Technology and Research's (A*STAR's) Genome Institute of Singapore (GIS), and the Singapore General Hospital (SGH), have devised a novel drug combination that could treat a particularly deadly form of leukaemia known as blast crisis (BC) chronic myeloid leukaemia (CML). The team has also developed strategies that may identify patients with early stage or chronic phase (CP) CML who are at increased risk of developing BC, and potentially preventing disease progression. https://medicalxpress.com/news/2020-03-common-therapeutic-vulnerability-genetically-diverse.html Wed, 18 Mar 2020 11:03:01 EDT news503748160 Patients with chronic myeloid leukemia can be treated with tyrosine kinase inhibitors. While these effective drugs lead to deep remission and prolonged survival, primitive leukemia stem cells resist elimination during the remission and persist as a major barrier to cure. https://medicalxpress.com/news/2019-06-sirt1-key-role-chronic-myeloid.html Tue, 11 Jun 2019 03:39:39 EDT news479443171 Clinical trial results published in the journal Nature Medicine show 91 percent response rate to the combination of venetoclax with azacitidine in older adults newly diagnosed with acute myeloid leukemia (AML). Of 33 patients given combination venetoclax and azacitidine, 20 experienced a complete response (aka complete remission) and eight experienced a complete response but with continued low blood counts. Of the three patients who did not respond to treatment, two discontinued the study before the first week due to personal reasons unrelated to treatment or side-effects. https://medicalxpress.com/news/2018-11-percent-response-venetoclax-newly-aml.html Wed, 28 Nov 2018 15:28:36 EST news462641302 Your body's blood cells are manufactured by hematopoietic stem cells in bone marrow. But just as regular, mature cells can become cancerous, so too can stem cells. When hematopoietic stem cells mutate in specific ways, the result can be damaged stem cells that create a type of pre-leukemic condition known as myelodysplastic syndrome, or MDS. On its own, MDS is a chronic condition that results in symptoms like anemia. In early stages, MDS can usually be managed with supportive care. However, as the disease progresses, about one in three cases of high-risk MDS will evolve into acute myeloid leukemia (AML), an extremely dangerous form of blood cancer that can be lethal. https://medicalxpress.com/news/2018-09-combination-treatment-pre-leukemia-stem-cells.html Wed, 12 Sep 2018 13:35:20 EDT news455978110 A drug called dasatinib was found to be safe and effective for children with chronic myeloid leukemia, according to a clinical trial published in the Journal of Clinical Oncology. https://medicalxpress.com/news/2018-04-pediatric-leukemia-treatment.html Thu, 12 Apr 2018 08:00:01 EDT news442737734 Two drugs, already approved for safe use in people, may be able to improve therapy for chronic myeloid leukemia (CML), a blood cancer that affects myeloid cells, according to results from a University of Iowa study in mice. https://medicalxpress.com/news/2017-09-prostaglandin-e1-inhibits-leukemia-stem.html Mon, 25 Sep 2017 15:03:02 EDT news425570570 The antibiotic tigecycline, when used in combination with current treatment, may hold the key to eradicating chronic myeloid leukaemia (CML) cells, according to new research. https://medicalxpress.com/news/2017-09-antibiotic-chronic-myeloid-leukaemia.html Tue, 19 Sep 2017 09:56:10 EDT news425033758 Researchers have found a way to identify rogue cancer cells which survive treatment after the rest of the tumour is destroyed, by using a new technique that enables them to identify and characterise individual cancer cells. https://medicalxpress.com/news/2017-05-cell-focus-reveals-hidden-cancer.html Tue, 16 May 2017 08:24:35 EDT news414141858 Scientists identify two signaling proteins in cancer cells that make them resistant to chemotherapy, and show that blocking the proteins along with chemotherapy eliminate human leukemia in mouse models. https://medicalxpress.com/news/2017-03-scientists-achilles-heel-treatment-resistant-cancers.html Mon, 20 Mar 2017 12:02:06 EDT news409230115 Scientists at the University of Glasgow have made a second significant breakthrough in the treatment of chronic myeloid leukaemia – using precision medicine to kill more than 90% of chronic myeloid leukaemia (CML) stem cells. The results are published today in the high impact journal Cancer Discovery. https://medicalxpress.com/news/2016-09-precision-medicine-breakthrough-chronic-myeloid.html Fri, 16 Sep 2016 04:18:26 EDT news393218292 A study in mice combining two inhibitor drugs for treatment of chronic myeloid leukemia (CML) has revealed potential for not only stopping the disease completely, but also significantly lowering the cost for treatment. CML is a cancer of the white blood cells accounting for 20 percent of adult leukemia. https://medicalxpress.com/news/2016-09-combination-therapy-chronic-myeloid-leukemia.html Wed, 07 Sep 2016 14:00:03 EDT news392443521 Chronic myeloid leukemia (CML) develops through chromosomal alterations in blood-forming cells of the bone marrow and usually occurs in older persons. Around 20 percent of adults diagnosed with leukemia suffer from this type of blood cancer. The protein Gab2 works as an enhancer of cancer-causing signals and is often present in larger quantities in CML cells than in healthy cells. In two studies, Freiburg researchers have made new discoveries concerning the relationship between CML and Gab2 and drugs that can break a particular resistance to Gab2 in CML cells. The team, including Dr. Tilman Brummer, Prof. Dr. Jörn Dengjel, Dr. Konrad Aumann, and Dr. Sebastian Halbach, published its findings in the journals Leukemia and Cell Communication and Signaling. https://medicalxpress.com/news/2016-06-resistant-blood-cancer-cells.html Mon, 20 Jun 2016 11:36:10 EDT news385641359 An international team of scientists, headed by researchers at UC San Diego School of Medicine and UC San Diego Moores Cancer Center, report that decreases in a specific group of proteins trigger changes in the cancer microenvironment that accelerate growth and development of therapy-resistant cancer stem cells (CSCs). https://medicalxpress.com/news/2015-11-discovery-embryonic-cancer-stem-cell.html Mon, 30 Nov 2015 17:18:29 EST news368126286 Common diabetes drugs might help eradicate drug-resistant cancer cells in a certain form of leukemia when added to standard treatment, a small new study suggests. https://medicalxpress.com/news/2015-09-common-diabetes-drugs-leukemia.html Wed, 02 Sep 2015 17:08:32 EDT news360432491 Metabolism experts are increasingly convinced that obesity and many of the pathogenic changes it entails, such as Metabolic Syndrome and type 2 diabetes, are a result of chronic inflammatory processes in fatty (adipose) tissue. The adipose tissue of obese people exhibits higher-than-normal quantities of almost all types of immune and inflammatory cells. https://medicalxpress.com/news/2015-06-calories.html Mon, 08 Jun 2015 11:39:06 EDT news352982339 Leukemia cells from chronic myeloid leukemia patients, especially those in the advanced stage, lack the BRCA1 protein. Importantly, the protein is not present even if the patient carries the proper, unmutated gene responsible for BRCA1 production. https://medicalxpress.com/news/2015-03-leukemia-achilles-weakness.html Thu, 26 Mar 2015 06:47:53 EDT news346571264